Every lot is tried & tested in a relevant biological assay.
- Thress, K. et al. (2009) Mol. Cancer. Ther. 8, 1818.
- Alomone Labs AZD-1332 inhibits NGF-mediated survival of serum-deprived PC12 cells.Dose-response curve of AZD-1332 (#A-495) inhibition of Native mouse NGF 2.5S protein (>95%) (#N-100) mediated survival of serum-deprived PC12 cells. Cell viability was determined by the XTT method and normalized to control. IC50 was calculated at 1.9 nM.
- Alomone Labs AZD-1332 inhibits BDNF-induced ERK1/2 (p42/44 MAPK) phosphorylation in TrkB-expressing HEK 293 cells.Serum-deprived cells were stimulated with 10 ng/ml Recombinant human BDNF protein (#B-250) in the presence of 0 nM, 5 nM, 50 nM and 500 nM AZD-1332 (#A-495). Cell proteins were resolved by SDS-PAGE and probed with anti-phospho-ERK1/2. Complete inhibition of signal is achieved at 50 nM.
AZD-1332 is a potent and selective inhibitor of the Tropomyosin-related kinase (TrkA, TrkB, and TrkC) receptors. The compound is at least 30-fold more specific towards Trk in cell-based assays over a wide range of other kinases tested. AZD-1332 inhibits Trk kinase activity in cells at low nanomolar concentrations, the compound demonstrates IC50 values of <10 nM for TrkA and TrkB1.
TrkA, TrkB, and TrkC receptors are involved in neuronal cell growth, development, and survival. Trk receptors are also potent oncogenes involved in malignant transformation, metastasis, and survival signaling in human tumors1,2.
AZD-1332 (#A-495) is a highly pure, synthetic, and biologically active compound.